Sign up
Pharma Capital

'All good news' from Motif Bio's Phase III clinical trial of Iclaprim, says CEO Graham Lumsden

Graham Lumsden, chief executive of Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) runs Proactive through the successful completion of a phase III clinical trial of their next-generation antibiotic, Iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).


View full MTFB profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.